Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
[OncoTargets and Therapy] This research evaluates the efficacy and toxicities of oral FU-based CRT compared with GEM-based CRT for the treatment of locally advanced pancreatic cancer (LAPC).
Researchers are working on a way to use artificial intelligence to predict a patient’s response to two common chemotherapy drugs used to treat breast cancer: paclitaxel and gemcitabine.
When giving gemcitabine (Gemzar) and cisplatin (Platinol), is it better to give gemcitabine first to reduce myelosuppression with every indication?
Transport properties identified on routine CT scans correlate with clinically relevant end points for patients with pancreatic ductal adenocarcinoma (PDAC) who receive preoperative gemcitabine chemoradiotherapy.
For patients with metastatic pancreatic cancer, treatment with albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine is more effective than gemcitabine alone.
Adjuvant treatment also improves disease-free survival compared with observation
Patients with advanced biliary cancer treated with cisplatin plus gemcitabine experience a significant survival advantage without added toxicity, according to a study published in The New England Journal of Medicine (2010;362(14):1273-1281).
